XML 34 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
Net Product Sales (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Dec. 31, 2013
Revenue Disclosure [Line Items]            
Branded Prescription Drug Fee   $ 40,600        
Net product sales $ 737,562 448,844 $ 1,939,954 $ 1,229,244    
Activity of Sales Related Deductions [Roll Forward]            
Balance 45,074 22,795 45,074 22,795 $ 24,781 $ 24,601
Provision related to current period sales     135,363 78,156    
Credits/payments     (115,070) (79,962)    
Rebates and Chargebacks            
Activity of Sales Related Deductions [Roll Forward]            
Balance 6,362 3,792 6,362 3,792 3,083 4,400
Provision related to current period sales     41,290 23,265    
Credits/payments     (38,011) (23,873)    
Distribution Related Fees            
Activity of Sales Related Deductions [Roll Forward]            
Balance 38,208 18,474 38,208 18,474 21,166 19,663
Provision related to current period sales     88,049 53,689    
Credits/payments     (71,007) (54,878)    
Other Sales Related Deductions            
Activity of Sales Related Deductions [Roll Forward]            
Balance $ 504 $ 529 504 529 $ 532 $ 538
Provision related to current period sales     6,024 1,202    
Credits/payments     $ (6,052) $ (1,211)    
Customer concentration risk | Gross Sales Revenue            
Risks and Uncertainties [Abstract]            
Concentration risk, percentage 65.00% 72.00% 67.00% 75.00%    
EYLEA            
Revenue Disclosure [Line Items]            
Net product sales $ 734,400 $ 445,000 $ 1,930,000 $ 1,218,800    
ARCALYST            
Revenue Disclosure [Line Items]            
Net product sales $ 3,200 $ 3,800 $ 9,900 $ 10,400